Azenta, Inc. · NASDAQ:AZTA
Azenta — Investor Day (December 2025)
67 slides from Azenta's investor day presentation, Dec 10, 2025
Slide 1: Investor Day 2025
INVESTOR DAY 2025 DECEMBER 10, 2025 © 2025 Azenta, Inc. • All rights reserved
Slide 2: Welcome & Opening Remarks
Welcome & Opening Remarks Yvonne Perron VP, Head of FP&A and Investor Relations © 2025 Azenta, Inc. • All rights reserved
Slide 3: Safe Harbor Statement
Safe Harbor Statement Forward-Looking Statements and Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act
Slide 4: Today's Agenda
Today’s Agenda 1:00 PM Welcome and Opening Remarks Yvonne Perron | VP, Head of FP&A and Investor Relations Company Overview and Strategy John Marotta | President and Chief Executive Officer Sample Management Solutions Alex Esmon | VP and GM of Sample Repository Solutions (SRS) Multiomics (GENEWIZ) G
Slide 5: Company Overview and Strategy
Company Overview and Strategy John Marotta President and CEO © 2025 Azenta, Inc. • All rights reserved
Slide 6: Key Messages
Key Messages Uniquely positioned with a strong top-line growth trajectory, meaningful 1 margin expansion potential, and clear opportunities for inorganic growth Category leader with best-in-class solutions in attractive, niche categories 2 tied to strong secular growth markets Deep installed base of
Slide 7: Large and Growing Addressable Market
Large and Growing Addressable Market Current SAM1: CURRENT EXPECTED EXPECTED ~$6B SMS2 Market Share3 Through Cycle Market Growth3 LRP 3-Yr Organic ~$3B Growth SMS ~11% LSD HSD Multiomics Multiomics ~9% LSD MSD ~$3B Significant Opportunity to Capture Share in a Large and Growing Market Source: 1. 202
Slide 8: Well-Positioned to Capitalize on Secular Growth Trends
Well-Positioned to Capitalize on Secular Growth Trends Life science spend Productivity is becoming FDA approval is substantial… Outsourcing trend… more essential… requirements are becoming more stringent… Private and Public Investment Growing Desire to Increasing Demand for Greater Need for Automate
Slide 9: Azenta Today
Azenta Today FY’25 REVENUE $594M Revenue +3% Organic YoY ~55% Recurring Revenue 1 20 of 20 1B+ 60M Samples 14,000 95 1 in 3 Employees is Top Pharma/ Samples currently stored Customers Countries a scientist/engineer Biotech supported at Azenta Revenue by Segment Revenue by End Market Geographic Mix 4
Slide 10: Initial Impressions Since Joining as CEO
Initial Impressions Since Joining as CEO STRONG FOUNDATION PIVOTING TO GROWTH & PERFORMANCE • Highly differentiated • Reorienting for success with accountable, regionalized GMs, and commercial teams portfolio of solutions creating an ecosystem • Elevating operational excellence with Azenta Business
Slide 11: Comprehensive Suite of Solutions to Enable Breakthroughs Faster
Comprehensive Suite of Solutions to Enable Breakthroughs Faster Guardians of the Most Critical Assets for Researchers Discovery + Pre Clinical Studies to Clinical Trials & Development Sample Management Solutions (SMS) Multiomics (GENEWIZ) Biorepositories Automated Gene Sequencing2 Solutions1 Synthes
Slide 12: The Only Player with Full Capabilities to Address Customers' Needs
The Only Player with Full Capabilities to Address Customers’ Needs Automated storage & integrated solutions Reading and writing Deep scientific Automation capabilities enabling genes increased research productivity expertise (3-10x increased research output) Software solutions Off-site biorepositori
Slide 13: Key Enabler of the Life Sciences Ecosystem
Key Enabler of the Life Sciences Ecosystem Customer Samples Customer Samples Partner with our customer to ensure integrity of samples during planning, collection, and transportation stages 0 0 0 Storage Samples are received and registered at the Azenta facility or on-site at the Interpret Asset Inta
Slide 14: Customers Searching for the Right Partner to Eliminate Pain Points
Customers Searching for the Right Partner to Eliminate Pain Points Fundamentally, automation Azenta has been a strong Azenta is an outstanding enables scale…Azenta is a partner to GSK over many partner in our crucial partner because years. The interactions to transformation journey… they support the
Slide 15: Executing Strategy to Drive Long-Term Value Creation
Executing Strategy to Drive Long-Term Value Creation for Shareholders DRIVE REINVEST DEPLOY Operational In Profitable Capital Prudently Excellence Growth and Strategically • Scale Biorepositories • Regionalize Synthesis • Technology and Automated Solutions © 2025 Azenta, Inc. • All rights reserved 1
Slide 16: Early Innings of Our Operational Excellence Journey
Drive Operational Excellence Early Innings of Our Operational Excellence Journey IMPLEMENTING AND EXECUTING ABS Manufacturing & Back-Office Efficiency • Driving safety, quality, and on-time delivery (OTD) • Optimizing working capital management Manufacturing & Back-Office Efficiency • Delivering enh
Slide 17: Early Successes in Operations & Manufacturing
Drive Operational Excellence Early Successes in Operations & Manufacturing FOCUS AREA WHAT WE HAVE DONE FUTURE PRIORITIES Store complaints reduced Improve Quality • Target <2% by 55% Enhance Delivery C&I OTD improved by 30% • >95% OTD • 10% additional G&A Reduce Costs G&A reduced by 3% improve
Slide 18: Delivering Growth across Three Core Vectors
Reinvest in Profitable Growth Delivering Growth across Three Core Vectors 1 2 3 Scale Biorepositories Regionalize Gene Continue to specialize Capitalize on coming wave of Synthesis in technology and sample growth Expand U.S. based production automated solutions to accelerate delivery & meet Deliver
Slide 19: Reinvigorating Our Go-to-Market Approach
Reinvest in Profitable Growth Reinvigorating Our Go-to-Market Approach KEY FOCUS AREAS HOW WE ARE EXECUTING • Installed localized sales & commercial team Regional sales model • Creating proximity to our customers to deepen relationships • Adjusted incentive plans to drive behavior Direct selling & •
Slide 20: Pursuing Targeted Actions to Drive Value Accretion
Deploy Capital Prudently and Strategically Pursuing Targeted Actions to Drive Value Accretion OUR PRIORITIES Productivity & GM Organic Growth M&A Share Repurchase Improvement Strengthen accountability Double down on growth Implement disciplined Renewed commitment through systematic and investments i
Slide 21: Strategic Approach to M&A
Deploy Capital Prudently and Strategically Strategic Approach to M&A Additive to Product line Commitment to disciplined M&A Current Portfolio Adjacencies Strategic capital deployment Economic, returns-driven approach Strategic Wallet Share Geographic Filters Expansion Expansion Stewards of cas
Slide 22: Leadership Team Excited and Poised for the Future
Leadership Team Excited and Poised for the Future John Marotta Lawrence Lin Ginger Zhou, PhD Olga Pirogova Ephraim Starr President & EVP & Chief SVP, President SVP, Chief Human SVP, General Chief Executive Financial GENEWIZ Resources Officer Counsel Officer Officer Joined: 2011 Joined: 2023 & Corpor
Slide 23: Dedicated and Experienced Board Creates Deeper Differentiation
Dedicated and Experienced Board Creates Deeper Differentiation Frank Casal William Cornog Martin Madaus Board Skills Chair of Azenta Board; Former head of KKR Senior Operating • CEO / CFO / Senior Executive Experience Former Vice Chair of Capstone Executive at Carlyle Audit at KPMG Group • Public Co
Slide 24: Investment Thesis and Value Creation
Investment Thesis and Value Creation Industry leader, Deep installed Above market Clear path to margin Financial strength with unmatched base, providing growth potential, expansion through and strong balance ecosystem of meaningful up-sell / supported by G&A efficiencies sheet fuels strategic, diffe
Slide 25: Sample Management Solutions (SMS)
Sample Management Solutions (SMS) Alex Esmon VP and GM, Sample Repository Solutions (SRS) © 2025 Azenta, Inc. • All rights reserved
Slide 26: Sample Management Solutions Key Messages
Sample Management Solutions Key Messages Leading the industry with expertise and a differentiated, end-to-end 1 solution set to manage and protect our customers’ irreplaceable assets Embedding the Azenta Business System into our way of working, 2 enabling us to execute with leading quality, efficien
Slide 27: Business Overview: Sample Management Solutions Today
Business Overview: Sample Management Solutions Today $325M ~50% 15%+ CAGR Our Vision FY’25 Revenue Recurring Revenue Growth of Samples in Storage (FY’15-FY’25) To become the end-to-end biological and therapeutic asset manager of 39% 4% APAC Other 47% Biorepositories Medical / choice from early resea
Slide 28: Well-Positioned to Capture Key Market Growth Drivers & Tailwinds
Well-Positioned to Capture Key Market Growth Drivers & Tailwinds ~$3B MARKET TAILWINDS Serviceable Addressable Market1 Increase in Pre-Clinical R&D Activity • Top pharma companies increasing R&D spend ~7% since 2020 • Increasing public and private annual investment - ~$250B public global Pharma/Biot
Slide 29: Sustainable Competitive Advantages
Sustainable Competitive Advantages END-TO-END Unique combination of sample storage SOLUTIONS products, services, consumables, and OFFERING software to fully support customer needs Trusted Differentiated Automation Data Reputation Expertise Capabilities Management Proven track record; Seasoned life s
Slide 30: Drive Operational Excellence
Drive Operational Excellence KEY INITIATIVES EXPECTED OUTCOMES Drive Process Improvement through ABS Integration Drive on time delivery 95% on time • Complete implementation of Lean management systems to improvement delivery scale more efficiently • Conduct ongoing Kaizens to drive continuous improv
Slide 31: Biorepositories: Reinvest in Profitable Growth
Biorepositories: Reinvest in Profitable Growth KEY INITIATIVES EXPECTED OUTCOMES Grow Customer Off-site Sample Storage Solutions • Deepen penetration by increasing the number and >100M types of samples stored Increase number of off-site samples stored samples stored by 2030 • Capitalize on scalabili
Slide 32: Automated Solutions: Reinvest in Profitable Growth
Automated Solutions: Reinvest in Profitable Growth KEY INITIATIVES EXPECTED OUTCOMES Elevate Digital Experience • Provide unified experience supported by Improve order harmonized software Streamlined customer / user experience conversion by 20% • Develop and release eCommerce platform Evolve leaders
Slide 33: Case Study: Unique Customer Solution
Case Study: Unique Customer Solution 1 Customer Need 2 Our Unique Solution 3 Results Results • Key customer in pharma production, • Created an integrated process connecting • Result 1st to market #1with an tasked with analyzing clinical and sample management, assay execution, and integrated • Result
Slide 34: Sample Management Solutions Key Takeaways
Sample Management Solutions Key Takeaways Leading the industry with expertise and a differentiated, end-to-end 1 solution set to manage and protect our customers’ irreplaceable assets Embedding the Azenta Business System into our way of working, 2 enabling us to execute with leading quality, efficie
Slide 35: Multiomics
Multiomics Ginger Zhou SVP, President GENEWIZ © 2025 Azenta, Inc. • All rights reserved
Slide 36: Multiomics (GENEWIZ) Key Messages
Multiomics (GENEWIZ) Key Messages Uniquely positioned with 26 years of sequencing & synthesis expertise 1 combined with unparalleled speed, convenience, and portfolio breadth making us a one-stop-shop Driving operational excellence leveraging the Azenta Business System 2 for customer satisfaction an
Slide 37: 26 Years of Reading and Writing Genes
26 Years of Reading and Writing Genes GENEWIZ To accelerate scientific discovery by providing researchers high-quality, reliable, VISION innovative multiomics solutions Sequencing Solutions Gene Synthesis Solutions Highest throughput Sequencing A manufactured gene of addressing complex studies gold
Slide 38: Business Overview: Multiomics (GENEWIZ) Today
Business Overview: Multiomics (GENEWIZ) Today TRUSTED PARTNER OF: $269M >70% FY’25 of Revenue from 120,000+ 8,000+ >37 Revenue Returning Customers Institutional Nobel End Users Customers Laureate Labs 5% APAC Other 37% Medical / 21% Gov / China Non-profit / 23% 77% 1 Academic & Sequencing Other Gene
Slide 39: Sustainable Competitive Advantages
Sustainable Competitive Advantages Trusted Brand with Speed & Deep Domain Knowledge Convenience One-Stop-Shop 26 years of know how, Regional footprint, providing Uniquely positioned with both emphasizing solid science & speed and convenience for synthesis & sequencing, fueling superior service clien
Slide 40: Well-Positioned to Capture Key Market Growth Drivers & Tailwinds
Well-Positioned to Capture Key Market Growth Drivers & Tailwinds ~$3B Serviceable MARKET TAILWINDS Addressable Market • Growth in outsourcing as Pharma & Biotechs optimize for efficiency ~$1.5B Sequencing Opportunity • Researchers have greater access to technologies at a lower cost ~$1.5B • Increase
Slide 41: Executing Strategic Initiatives to Drive Shareholder Value
Executing Strategic Initiatives to Drive Shareholder Value D R I V E Operational Excellence R E I N V E S T In Profitable Growth ABS Toolbox Implementation Synthesis Regionalization • Further improve deliverable speed and quality • Expand U.S. based production to accelerate delivery & • Continue to
Slide 42: Case Study: Supporting Clinical Trials Targeting Rare Childhood Disease
Case Study: Supporting Clinical Trials Targeting Breakthrough Solution for Rare Childhood Disease 1 Customer Need 2 Our Unique Solution 3 Results • Customer planning Phase 1 trial • GENEWIZ proposed a unique solution to treat rare childhood disease resulting in blindness leveraging long-read sequenc
Slide 43: Multiomics (GENEWIZ) Key Takeaways
Multiomics (GENEWIZ) Key Takeaways Uniquely positioned with 26 years of sequencing & synthesis expertise 1 combined with unparalleled speed, convenience, and portfolio breadth making us a one-stop-shop Driving operational excellence leveraging the Azenta Business System (ABS) 2 for customer satisfac
Slide 44: Financial Overview
Financial Overview Lawrence Lin Executive Vice President and CFO © 2025 Azenta, Inc. • All rights reserved
Slide 45: Key Messages
Key Messages Building on a strong financial foundation with key initiatives in place to drive 1 revenue growth 2 Capturing meaningful margin expansion opportunities through gross margin expansion and G&A efficiencies 3 Driving increased expense discipline and cost optimization to increase reinvestme
Slide 46: Initial Impressions since Joining as CFO
Initial Impressions since Joining as CFO STRONG FOUNDATION PIVOTING TO GROWTH WITH CLEARLY IDENTIFIED IMPROVEMENT AREAS • Portfolio and product differentiation • Implementing systematic process improvements • Talent and desire of team members to • Creating product line P&L and financial rigor win an
Slide 47: Driving Growth through Strategic Investments
Driving Growth through Strategic Investments Key Areas for Strategic Organic Growth Investments 1 Scale Biorepositories • Continuing to expand SRS facilities and increase automation • Grow off-site and on-site storage solutions 2 Regionalize Gene Synthesis • Expand U.S. based production to accelerat
Slide 48: Driving Margin Improvement through Strategic Investments
Driving Margin Improvement through Strategic Investments Margin Expansion Initiatives 1 Optimizing G&A for greater operational leverage • Improving processes while aligning the right resources to the right work 2 Pursuing price optimization • Implementing strategies for pricing optimization 3 Accele
Slide 49: Balanced and Disciplined Capital Allocation Strategy
Balanced and Disciplined Capital Allocation Strategy Ample Liquidity and Improving Free Cash Flow Long-term Capital Allocation Priorities Generation to Fund Capital Deployment Productivity & Gross Margin Improvement 1 • Reinvest to drive operational efficiencies • Accelerated adoption of ABS across
Slide 50: Strategic Approach to M&A
Strategic Approach to M&A Evaluate through Strategic Lens Greater Commitment to Disciplined M&A Additive to Product line with Financial Guiding Principles Current Portfolio Adjacencies Strong Organic Growth Potential Wallet Share Geographic Margin Expansion Potential / Synergies Expansion Expans
Slide 51: Reiterating 2026 Guidance
Reiterating 2026 Guidance FY’2026 Organic Growth: 3% to 5% YoY Revenue Sample Management Solutions: MSD Multiomics: LSD Adjusted EBITDA 300 bps of Adjusted EBITDA margin expansion Interest Income: $16M - $18M Other Tax Rate: 27% - 29% Continuing to Track Toward Our Previously Announced Targets Note:
Slide 52: Introducing 2028 Organic Financial Targets
Introducing 2028 Organic Financial Targets $700 - $750M 70% $120 - $150M $200 - $250M Revenue Recurring Adj. EBITDA Cumulative Revenue2 3-Year 6% - 8% CAGR1 18 - 20% Free Cash Flow4 Adj. EBITDA Margin3 Well-Positioned to Drive Performance Improvement and Create Value for All Stakeholders 1. 2025-202
Slide 53: Revenue Bridge
Revenue Bridge ~20% ~20% $700M - $750M Key Assumptions ~35% ~25% • C&I • Direct Selling • LSD market growth $594M • Scale / Expand • Multiomics • Regionalization • Product Marketing • LSD Market Biorepositories • Strategic initiatives and Growth • Gene Synthesis • Modular Vaults NPI contribute >50%
Slide 54: Adjusted EBITDA Margin Bridge
Adjusted EBITDA Margin Bridge Key Annual Assumptions ~3% ~18% - 20% • Gross margin expands ~2-3% >200bps • G&A and Indirect savings ~2-3% yield 100bps 11% • Adj. EBITDA expands ~300bps +700 - 900 bps expansion FY'25 Adj. Volume & Mix Productivity Procurement, FY'28E Adj. EBITDA Margin G&A Savings EB
Slide 55: Key Takeaways
Key Takeaways Building on a strong financial foundation with key initiatives in place to 1 drive revenue growth and margin improvement 2 Capturing meaningful margin expansion opportunities through gross margin expansion and G&A efficiencies 3 Increasing reinvestment in the business to drive future r
Slide 56: Closing Remarks
Closing Remarks John Marotta President and CEO © 2025 Azenta, Inc. • All rights reserved
Slide 57: Investment Thesis and Value Creation
Investment Thesis and Value Creation Industry leader, Deep installed with unmatched base, providing ecosystem of meaningful up-sell / differentiated cross-sell potential customer solutions and strong recurring revenue Financial strength and Above market growth strong balance sheet potential, support
Slide 58: Break
Break © 2025 Azenta, Inc. • All rights reserved
Slide 59: Q&A
Q&A © 2025 Azenta, Inc. • All rights reserved
Slide 60: Appendix
Appendix © 2025 Azenta, Inc. • All rights reserved
Slide 61: Solid Financial Position
Solid Financial Position Adjusted EBITDA ($M) Revenue ($M)1 and Margin (%)1 $594 $66 610 70 20.00% 590 $573 18.00% 60 16.00% $46 570 $551 50 14.00% +3.7% 11.2% 550 12.00% CAGR 40 530 8.0% 10.00% 30 $22 8.00% 510 4.0% 6.00% 20 490 4.00% 10 470 2.00% 450 0 0.00% FY'2023 FY'2024 FY'2025 FY'2023 FY'2024
Slide 62: Net Income to Adjusted EBITDA Reconciliation
Net Income to Adjusted EBITDA Reconciliation Continuing Operations $ millions except percentages FY23 FY24 FY25 Net income (14.7) (164.9) (58.7) (Income) Loss from discontinued operations, net of tax 6.6 140.5 83.2 Net income (Loss) from continuing operations (8.1) (24.4) 24.5 Adjustments: Interest
Slide 63: Speaker Bios
Speaker Bios © 2025 Azenta, Inc. • All rights reserved
Slide 64: John Marotta
John Marotta President and CEO Mr. Marotta joined Azenta Life Sciences in September 2024 as President and CEO. He has two decades of experience leading global companies in life sciences, medical devices, and diagnostics. Prior to joining the company, Mr. Marotta served as Executive in Residence of P
Slide 65: Lawrence Lin
Lawrence Lin Executive Vice President and CFO Mr. Lin joined Azenta in November 2024 as Executive Vice President and Chief Financial Officer and brings over twenty years of finance experience. Prior to joining Azenta, Mr. Lin was Chief Financial Officer at GeoStabilization International LLC (“GSI”),
Slide 66: Alex Esmon, PhD
Alex Esmon, PhD VP and GM, Sample Repository Solutions (SRS) Alex Esmon joined Azenta Life Sciences in January 2023 and was appointed Vice President and General Manager of the Sample and Repository Solutions business in April 2025. He is responsible for driving growth and operational efficiencies an
Slide 67: Ginger Zhou, PhD
Ginger Zhou, PhD SVP, President GENEWIZ Ginger Zhou joined Azenta Life Sciences in November 2018 and was appointed Senior Vice President and General Manager of the GENEWIZ Multiomics and Synthesis Solutions business in November 2022. She holds primary responsibility for leading global GENEWIZ Multio